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Abstract
Background: Defined as estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2, chronic kidney disease
(CKD) is strongly and independently associated with cardiovascular and overall mortality. We hypothesized that
reduced kidney function would be characterized by abnormalities of hemostasis.
Methods: We tested cross-sectional associations between (eGFR) and multiple hemostatic markers among 6751
participants representing a broad spectrum of kidney function in the Multi-Ethnic Study of Atherosclerosis (MESA).
Kidney function was measured using cystatin C (eGFRcys) or creatinine, using CKD Epidemiology Collaboration
(eGFRcr). Hemostatic markers included soluble thrombomodulin (sTM), soluble tissue factor (sTF), D-Dimer, von
Willebrand factor (vWF), factor VIII, plasmin-antiplasmin complex (PAP), tissue factor pathway inhibitor (TFPI),
plasminogen activator inhibitor-1 (PAI-1), and fibrinogen. Associations were tested using multivariable linear
regression with adjustment for demographics and comorbidities.
Results: In comparison to persons with eGFRcys >90 ml/min/1.73 m
2, subjects with eGFRcys < 60 ml/min/1.73 m
2
had adjusted levels of sTM, sTF, D-Dimer, PAP, Factor VIII, TFPI, vWF and fibrinogen that were respectively 86%,
68%, 44%, 22%, 17%, 15%, 12% and 6% higher. Subjects with eGFRcys 60-90 ml/min/1.73 m
2 had adjusted levels
that were respectively 16%, 14%, 12%, 6%, 6%, 6%, 11% and 4% higher (p < 0.05 for all). Percent differences were
not significantly different when groups were categorized by eGFRcr.
Conclusions: Throughout a broad spectrum of kidney function, lower eGFR was associated with higher levels of
hemostatic markers. Dysregulation of hemostasis may be a mechanism by which reduced kidney function
promotes higher cardiovascular risk.
Background
Defined as estimated glomerular filtration rate (eGFR)
<60 ml/min/1.73 m
2, chronic kidney disease (CKD)
stage 3 to 5 [1] is an established risk factor for cardio-
vascular morbidity and mortality [2,3]. This association
begins in the pre-clinical stages of kidney disease, when
kidney function may be better estimated by cystatin C
(eGFRcys) [4-6]. The mechanisms underlying the asso-
ciation of CKD with cardiovascular morbidity and mor-
tality are inadequately understood. In multiple cohorts
with and without CKD, the associations of lower eGFR
with higher cardiovascular risk persist despite adjust-
ment for traditional risk factors and inflammation
[7-10], prompting investigation into novel pathways
between renal and cardiovascular disease (CVD).
Atherosclerosis represents a pernicious interplay
between systems of inflammation and coagulation [11].
Multiple investigators have reported an association
between creatinine-based CKD and elevated levels of
inflammatory and thrombotic markers [12,13]. In studies
from the Health, Aging and Body Composition Study and
the Multi-Ethnic Study of Atherosclerosis (MESA), sub-
jects with mildly reduced kidney function measured with
cystatin C had only modest elevations in inflammatory
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any medium, provided the original work is properly cited.markers [13-16]. Furthermore, the positive association of
cystatin C with cardiovascular and overall mortality is only
partially attenuated by adjustment for C-reactive protein
(CRP), interleukin-6 (IL-6) or TNF-a [5,6]. However,
whether or not dysregulation of hemostasis contributes to
the association of CKD and CVD has not been well
evaluated.
We designed these analyses to explore the associations
of reduced kidney function, as measured by eGFRcys
and CKD Epidemiology Collaboration (eGFRcr), with
hemostatic factors in an ethnically diverse cohort free of
clinical cardiovascular disease.
Methods
Subjects
We conducted a cross-sectional analysis of 6751 partici-
pants in the Multi Ethnic Study of Atherosclerosis
(MESA) at the baseline visit (July 2000 to July 2002).
Soluble thrombomodulin (sTM), soluble tissue factor
(sTF) and tissue factor pathway inhibitor (TFPI) were
measured in a random sample of 1000 MESA partici-
pants; the other markers were measured in nearly the
whole cohort. MESA is a cohort study sponsored by the
National Heart, Lung, and Blood Institute aimed to
improve understanding of subclinical cardiovascular dis-
ease and its progression in a multiethnic cohort. Details
on recruitment and design have been published [17].
Briefly, MESA recruited 6,814 men and women between
the ages of 45 and 84 years, who were free of cardio-
vascular disease and self-identified as white, African
American, Hispanic, or Chinese-American. Subjects
were recruited from Baltimore City and Baltimore
County, Maryland; Chicago, Illinois; Forsyth County,
North Carolina; Los Angeles County, California; north-
ern Manhattan and the Bronx, New York; and St. Paul,
Minnesota, between July 2000 and August 2002. Indivi-
duals were excluded if they had physician-diagnosed
heart attack, angina, heart failure, stroke or transient
ischemic attack, or atrial fibrillation; if they had under-
gone coronary artery bypass grafting, angioplasty, valve
replacement, or pacemaker insertion; or if they weighed
> 300 pounds (>136 kg). The institutional review boards
at all participating centers approved the study, and all
participants gave informed consent.
Primary predictors
Cystatin C was measured in plasma using a BNII
nephelometer on plasma specimens (Siemens Latex N-
Latex cystatin C assay). Estimated glomerular filtration
rate by cystatin C (eGFRcys) was calculated using the
formula: 76.7 × cys C
-1.19. This formula was developed
from pooled data from several cohorts with eGFR mea-
sured by iothalamate [18]. Serum creatinine was mea-
sured using colorimetry with a Johnson & Johnson
Vitros 950 analyzer (Johnson & Johnson Clinical Diag-
nostics Inc., Rochester, NY). Creatinine levels were cali-
brated to the Cleveland Clinic standard (0.9954*Cr +
0.0208) [19]. The eGFRcr equation was used to calculate
creatinine - based eGFR (eGFRcr) [20].
Primary outcomes
Soluble thrombomodulin (sTM) was measured by
enzyme immunoassay using a monoclonal antibody to
TM as the capture antibody (Asserachrom Thrombomo-
dulin, Diagnostica Stago; Asnières-sur-Seine, France, CV
1 2 % ) .S o l u b l et i s s u ef a c t o r( s T F )w a sm e a s u r e db ya n
enzyme-linked immunoassay that employs an anti-TF
monoclonal capture antibody (Imubind Tissue Factor
ELISA Kit, American Diagnostica, Inc.; Stamford, CT,
CV 14.6%). Total tissue factor pathway inhibitor (TFPI)
was measured by enzyme-linked sandwich ELISA using
a polyclonal anti-TFPI antibody as the capture antibody
(Imubind Total TFPI ELISA Kit, American Diagnostica,
Inc.; Stamford, CT). Intra-assay and inter-assay analyti-
cal CVs range from 6.2-7.1% and 5.5-7.3%, respectively.
Fibrin fragment D-dimer was measured using an
immuno-turbidimetric assay (Liatest D-DI; Diagnostica
Stago, Parsippany, NJ) on the Sta-R analyzer (Diagnos-
tica Stago, Parsippany, NJ, CV 8%). Plasmin-antiplasmin
complex (PAP) was measured in an assay that detects
o n l yp l a s m i ni nc o m p l e xw i t ha2-antiplasmin, and
not free plasmin or a2-antiplasmin, CV 1.7%. von
Willebrand factor was measured by an immunoturbido-
metric assay on the Sta-R analyzer (Diagnostica Stago,
Parsippany, NJ). The intra-assay and inter-assay analyti-
cal CV’s are 3.7% and 4.5%, respectively. Factor VIII
coagulant activity was determined by measuring the
clotting time of a sample in factor VIII deficient plasma
in the presence of activator (STA-Deficient VIII; Diag-
nostica Stago, Parsippany, NJ). Fibrinogen was measured
using a BNII nephelometer (N Antiserum to Human
Fibrinogen; Siemens) with intra-assay and inter-assay
analytical CV’s of 2.7% and 2.6%, respectively. Plasmino-
gen activator inhibitor-1 (PAI-1) was measured by a
two-site ELISA [21].
Variables of interest
Blood pressure measurements were obtained by using
an automated blood pressure device (DINAMAP PRO
100 monitor; General Electric Healthcare) following JNC
guidelines [22]. Hypertension was defined as self-report
of physician diagnosis, use of anti-hypertensive agents,
or SBP > = 140, or DBP > = 90. Diabetes was defined
by fasting glucose > = 126 or the use of hypoglycemic
medication or insulin. Tobacco use was defined by cur-
rent smoking. Height and weight were measured with
participants wearing light clothing and no shoes. Body
mass index was calculated as weight (kg)/height (m)
2.
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until analyzed for total and high density lipoprotein cho-
lesterol, triglycerides and glucose. Low density lipopro-
tein cholesterol was calculated by using the Friedewald
equation.
Statistical analysis
We compared sociodemographic and anthropometric
factors as well as comorbidities among subjects with
eGFRcys > 90, 60-90 and < 60 ml/min/1.73 m
2 using
ANOVA, Kruskal-Wallis test, or chi-square tests as
appropriate. Using multivariable linear regression, we
studied the associations between continuous eGFR and
each of the seven biomarkers, using both eGFRcys and
eGFRcr. Each biomarker was natural log transformed,
and beta coefficients were transformed into percent dif-
ferences using (e^b-1)*100 to allow comparison across
outcomes. In additional analyses we defined eGFR
groups as >90, 60-90 and <60 ml/min/1.73 m
2,a n dw e
compared the percent difference in each biomarker with
eGFR > 90 as the reference. The fully adjusted models
included age, race/ethnicity (white, black, Hispanic, Chi-
nese), gender, annual income, study site, current smok-
ing, current alcohol use, BMI, DM, HTN, statin use,
ACE-I, LDL cholesterol, HDL cholesterol, triglycerides,
fasting glucose, and ln(albumin/creatinine). All models
assumptions for linear regression, including linearity,
homoscedasticity and normality, were checked. Analyses
were preformed in SAS V 9.1.3 (SAS Institute, Cary,
N C ) ,a n dp<0 . 0 5w a sc o n s i d e r e da st h et h r e s h o l df o r
statistical significance.
Results
Participants’ characteristics
Among the 6751 participants, the mean age was 62
years; 53% were women; 38% were white, 27% black,
22% Hispanic, and 12% Chinese-American. The preva-
lences of diabetes and hypertension were 14% and 45%,
respectively. Average eGFRcys was 92 ml/min/1.73 m
2
and average eGFR by eGFRcr was 79 ml/min/1.73 m
2 .
Compared to those without CKD, subjects with CKD
with eGFRcys <60 ml/min/1.73 m
2 were older, had a
higher prevalence of diabetes and hypertension, higher
rate of ACE-I and statin use, higher fasting glucose, tri-
glycerides and urinary albumin to creatinine ratio, lower
HDL and LDL, and lower rate of alcohol use. (Table 1)
Variation by race/ethnicity and correlations among
biomarkers
We analyzed levels of hemostatic markers in different
groups of race/ethnicity. sTM showed significant hetero-
geneity by race/ethnicity: Caucasians and Hispanics had
significantly higher sTM than African-Americans and
Chinese. Levels of vWF, and fVIII were significantly
higher in African-Americans, and fibrinogen was
higher in African Americans and Hispanics. (Table 2)
As expected, many of the hemostatic biomarkers were
highly correlated. vWF and factor VIII were positively
correlated (r = 0.66); PAP and PAI-1 were inversely
correlated, ( r = -0.48). D-Dimer had moderate correla-
tions (r = 0.23-0.34) with VWF, factor VIII, PAP
and fibrinogen. Fibrinogen had moderate correlations
(r = 0.23-0.38) with vWF, factor VIII, PAP, and TFPI
(p < 0.05 for all). No other strong correlations were
observed. (Table 3)
Associations between eGFR and biomarkers
We analyzed the associations between continuous mea-
sures of eGFR measured by both eGFRcys and eGFRcr
equations and the seven biomarkers. In models adjusted
for sociodemographics and comorbidities, sTM and sTF
had strong correlations with eGFR by either method.
For every 10 ml/min/1.73 m
2 lower eGFRcys, sTM was
7% higher (p < 0.001) and sTF was 6% higher (p <
0.001). D-Dimer, vWF, Factor VIII, PAP and TFPI had
moderate associations with eGFR using either method.
D-Dimer was 5% higher, vWF was 3% higher, and the
other three were 2% higher for every 10 ml/min/1.73 m
2
lower eGFRcys (p < 0.001 for all). PAI-1 was associated
with eGFRcys but not eGFRcr; fibrinogen had a weak
but statistically significant association with both GFR
estimates. (Table 4)
In addition, we calculated percent differences for each
marker between subjects grouped by eGFR, using eGFR
> 90 ml/min/1.73 m
2 as the reference. The group with
eGFRcys <60 ml/min/1.73 m
2 had an 86% higher sTM
level, 68% higher sTF, 44% higher D-Dimer, 12% higher
vWF, 17% higher Factor VIII, 22% higher PAP, 15%
higher TFPI, 6.5% higher PAI-1, and 6.3% higher fibri-
nogen. Participants with eGFR 60-90 ml/min/1.73 m
2
had significantly higher levels of all biomarkers ranging
from 16% for sTM to 3.8% for fibrinogen. (Figure 1)
Discussion
In a large, multiethnic cohort free of cardiovascular dis-
ease and with a spectrum of kidney function ranging
from normal to moderate CKD, even small decrements
in eGFR were associated with significantly higher levels
of sTM, sTF, D-Dimer, vWF, factor VIII, PAP and TFPI.
Our results suggest that dysregulation of hemostasis
could play an important pathologic role in CKD. In par-
ticular, these associations may help to explain the con-
sistently strong and independent associations of cystatin
C with cardiovascular and overall mortality, despite
adjustment for known risk factors including CRP [5],
IL-6 and TNF-a [6].
Soluble thrombomodulin and soluble tissue factor had
the largest associations with eGFRcys. sTM is a receptor
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cells. Injured endothelial cells release sTM into the circu-
lation, where it binds thrombin, inhibiting it from forming
fibrin and activating platelets. sTM has additional anti-
thrombotic activity as a cofactor for the thrombin-
catalyzed activation of protein C [23]. Elevated sTM is
associated with lower eGFR in CKD and end stage renal
disease ESRD [24,25], and our results extend these find-
ings to a broader spectrum of eGFR. The association of
sTM and cardiovascular disease varies by patient
population: in healthy individuals, lower sTM predicts cor-
onary heart disease (CHD), but in patients with established
CHD, higher sTM levels are associated with recurrence of
CHD and with higher mortality [26]. Whether higher
levels of sTM are associated with CVD or mortality in our
cohort would require further investigation.
Tissue factor (TF) initiates the extrinsic coagulation
cascade. Smooth muscle cells, adventitial fibroblasts, and
pericytes constitutively express TF, but endothelial cells
express TF only after injury [27]. TF has a prominent
Table 1 Demographic and clinical characteristics of MESA participants by groups of eGFRcys, 2000-2002
eGFRcys <60 (n = 376) eGFRcys 60-90 (n = 2746) eGFRcys >90 (n = 3629) P Value*
Age, years† 71 ± 9 66 ± 10 59 ± 9 <0.001
Female, n(%) 185 (49) 1131 (48) 2066 (57) <0.001
Race/Ethnicity, n(%) <0.001
Caucasian 165 (44) 1151 (42) 1286 (35)
African-American 103 (27) 715 (26) 1048 (29)
Hispanic 72 (19) 617 (23) 795 (22)
Chinese-American 36 (10) 263 (10) 500 (14)
Current Smoker, n(%) 50 (13) 386 (14) 440 (12) 0.08
Current Alcohol Use, n(%) 169 (45) 1457 (53) 2087 (58) <0.001
BMI, kg/m
2 30 ± 6 29 ± 6 28 ± 5
Prevalent Diabetes, n(%) 94 (25) 401 (15) 464 (13) <0.001
Prevalent Hypertension, n(%) 272 (72) 1451 (53) 1310 (36) <0.001
ACE Inhibitor Use, n(%) 113 (30) 501 (18) 410 (11) <0.001
Statin Use, n(%) 77 (21) 465 (17) 459 (13) <0.001
Fasting Plasma Glucose, mg/dl 111 ± 34 105 ± 29 104 ± 32 <0.001
Triglycerides, mg/dl§ 131 (93, 180) 126 (88, 179) 107 (77, 157) <0.001
HDL Cholesterol, mg/dl 47 ±14 49 ± 14 53 ±15 <0.001
LDL Cholesterol, mg/dl 114 ± 35 116 ± 6 118 ± 31 0.01
Urinary Creatinine, mg/dl‡ 96 (65, 142) 111 (66, 163) 106 (55, 162) 0.001
Urine Albumin/Creatinine, mg/g 10 (5, 47) 6 (3, 12) 5 (3, 10) <0.001
Serum Creatinine, mg/dl 1.4 ± 0.8 1.0 ± 0.2 0.9 ± 0.2 <0.001
eGFR Creatinine, ml/min/1.73 m
2 52 ± 17 73 ± 14 87 ± 14 <0.001
eGFR Cystatin, ml/min/1.73 m
2 50 ± 10 78 ± 8 108 ± 15 <0.001
*P-values obtained using ANOVA.
†Unless otherwise noted, Mean (SD).
‡Median (Quartile 1, Quartile 3).
Table 2 Levels of hemostatic markers by racial/ethnic group*
All Caucasian African-American Chinese Hispanic P Value**
Soluble Thrombomodulin, ng/ml 35 (16, 45) 36 (27, 47) 32 (23, 42) 31 (23, 40) 37 (27, 46) <0.001
Soluble Tissue Factor, pg/ml 106 (68, 156) 107 (66, 149) 106 (72, 175) 97 (65, 169) 108 (68, 155) 0.53
D-dimer, ug/ml 0.20 (0.13, 0.37) 0.20 (0.13, 0.35) 0.25 (0.15, 0.44) 0.18 (0.10, 0.30) 0.23 (0.13, 0.41) <0.001
von Willebrand Factor, % 130 (99, 169) 124 (95, 166) 144 (113, 199) 130 (96, 168) 127 (96, 166) <0.001
Factor VIII, % 93 (73, 120) 90 (70, 115) 100 (77, 131) 93 (73, 115) 91 (74, 117) <0.001
Plasmin Antiplasmin, nM 4.4 (3.4, 5.6) 4.4 (3.4, 5.6) 4.8 (3.8, 6.2) 3.9 (3.1, 4.9) 4.3 (3.4, 5.4) <0.001
Tissue Factor Pathway Inhibitor, ng/ml 48 (38, 57) 49 (38, 57) 48 (40, 58) 40 (33, 50) 49 (40, 58) <0.001
Plasminogen Activator Inhibitor-1, ng/ml 19 (10, 36) 19 (9, 34) 17 (8, 33) 24 (12, 39) 21 (11, 40) 0.02
Fibrinogen, mg/dl 338 (295, 389) 328 (286, 373) 353 (304, 406) 323 (287, 366) 352 (308, 401) <0.001
*Levels displayed as median (Quartile 1, Quartile 3).
**By Kruskal-Wallis test for difference among racial/ethnic groups.
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ary syndrome (ACS). TF is concentrated in the core of
the atherosclerotic plaque; when the plaque ruptures,
TF comes into contact with blood, binds factor VII and
initiates the extrinsic coagulation cascade [28]. Higher
levels of sTF were reported previously in CKD as com-
pared to healthy subjects [29]. Epidemiological studies
of sTF and CVD occurrence in healthy individuals are
lacking, but in patients with ACS, high levels of sTF on
admission are associated with poor outcome [30]. To
our knowledge this paper is the first to report an asso-
ciation between higher sTF and lower eGFR in patients
without CKD. Whether high levels of sTF contribute to
the high cardiovascular mortality of persons with kidney
disease is unknown.
D-Dimer, vWF, Factor VIII, and PAP showed moderate
associations with lower eGFRcys. Elevated levels of
D-Dimer are associated with lower eGFR [12] and CVD
[31] across the spectrum of eGFR. vWF is increased in
subjects with CKD [32], and it is considered to be a mar-
ker for endothelial dysfunction [33] and CVD risk
[34,35]. Factor VIII is increased in subjects with CKD
[12,32]. In the Atherosclerosis Risk in Communities
(ARIC) Study, factor VIII was associated with progression
of CKD and with fatal MI [36]. In MESA, Factor VIII was
associated with overall but not cardiovascular mortality
[37]. Plasmin, an enzyme that increases fibrinolysis, is
inactivated when complexed with a2-antiplasmin to form
PAP [11]. Subjects with CKD have higher levels of PAP
than subjects without CKD [12]. In a cohort with CAD,
PAP was associated with higher CVD risk [38]; in the
Cardiovascular Health Study (CHS), PAP was associated
with incident myocardial infarction [39].
Several of the hemostatic markers evaluated in this
study are strong risk factors for venous thomboembolic
disease, including D-dimer, factor VIII, and vWF [40].
Recent epidemiological studies have linked CKD with
risk of venous thrombosis [41,42]. Thus, our findings
may be applicable to both arterial and venous thrombo-
sis, and these associations may extend into higher levels
of kidney function than previously appreciated.
There are several possible mechanisms to explain the
association of lower eGFR and higher levels of hemostatic
factors. A direct effect of decreased renal clearance may
explain an increase in levels of smaller molecular weight
hemostatic markers such as sTF and sTM, as these may
be filtered at the glomerulus. Fragments of sTM ranging
from 28 to 108 kDa can be detected in blood and urine
[43]. Soluble tissue factor has a MW of 29 kDa. Urinary
tissue factor, with MW of 34 kDa, is elevated in glomeru-
lonephritis and various malignancies, but it is thought to
originate from the kidneys, rather than being blood
borne and filtered at the glomerulus [44]. Whether sTF
and sTM are filtered at the glomerulus would have to be
tested in animal studies. Given the higher molecular
weight of D-Dimer, vWF, factor VIII and PAP, it seems
unlikely that these markers are elevated as a direct result
of decreased renal clearance. It is possible that elevations
in these markers relate to processes initiated by smaller
molecules. Conversely, kidney dysfunction may generate
a thrombotic milieu indirectly through electrolyte or
acid-base abnormalities, which may alter activities of
enzymes involved in coagulation. Inflammation asso-
ciated with lower eGFR may cause elevations in markers
that are acute phase reactants. Alternatively, microvascu-
lar disease may promote the development of CKD, and in
Table 3 Spearman correlations among hemostatic
markers
sTM STF D-
dimer
vWF Factor
VIII
PAP TFPI PAI-
1
Fib
sTM –
STF 0.15†–
D-
dimer
0.05 0.04 –
vWF 0.15† 0.09** 0.25†–
Factor
VIII
0.10** 0.02 0.23† 0.66†–
PAP -0.03 0.15† 0.34† 0.25† 0.21†–
TFPI 0.21† 0.08* 0.14† 0.16† 0.16† 0.10** –
PAI-1 0.08* -0.08* 0.02 0.05 0.07* -0.48† 0.13†–
Fib 0.03 0.07* 0.29† 0.26† 0.24† 0.38† 0.23† 0.08* –
*0.01-<0.05.
**0.001-<0.01.
†<0.001.
Table 4 Cross-sectional associations of eGFR measures
with hemostatic markers in MESA, 2000-2002: percent
difference in hemostatic marker per 10 ml/min/1.73 m
2
decrement in eGFR*
eGFRcys, % (95%
CI)
eGFRcr, % (95%
CI)
Soluble Thrombomodulin 7.4 (5.9, 8.8) 8.2 (6.3, 10.1)
Soluble Tissue Factor 6.1 (3.6, 8.5) 7.6 (4.4, 10.6)
D-dimer 4.6 (3.5, 5.7) 4.7 (3.3, 6.1)
Von Willebrand Factor 2.8 (1.4, 4.2) 2.8 (0.93, 4.6)
Factor VIII 2.2 (2.7, 1.8) 1.8 (2.5, 1.2)
Plasmin-Antiplasmin
Complex
2.2 (1.7, 2.7) 3.2 (2.6, 3.8)
Tissue Factor Pathway
Inhibitor
2.1 (1.2, 3.1) 1.4 (0.2, 2.6)‡
Plasminogen Activator
Inhibitor-1
4.7 (2.0, 7.4) 1.3 (-2.3, 5.1)§
Fibrinogen 1.0 (0.74, 1.2) 1.0 (0.64,1.3)
*Note: Models adjusted for age, race, gender, SES (income), site, current
smoking, current alcohol, BMI, prevalent DM, prevalent HTN, statin use, ACE-I,
LDL, HDL, TG, fasting glucose, and ln(albumin/creatinine). All p values are
<0.001 unless otherwise noted.
‡p < 0.05.
§Non-significant.
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markers; in this scenario, the markers would be neither
cause nor effect of lower eGFR.
A strength of this study is the unique setting, as
MESA is a large, well-characterized cohort including
four major race/ethnic groups. The use of cystatin C to
measure eGFR increases our ability to detect associa-
tions of biomarkers across a broader spectrum of kidney
function. However, there are important limitations to
our study. As is typical for most large epidemiological
s t u d i e s ,w ed i dn o tu s eag o l ds t a n d a r dm e a s u r eo f
eGFR, such as iothalamate or iohexol clearance. Due to
the cross-sectional design, we cannot ascertain the
direction of association; it is equally possible that
increased levels of thrombotic markers causes decreased
eGFR, or that decreased eGFR causes the elevated mar-
kers. Finally, residual confounding may exist in our ana-
lysis, which may account for some of our findings, but
would be less likely to account for the strong associa-
tions of eGFRcys with sTM and sTF.
Conclusions
In summary, lower eGFR was significantly associated with
higher levels of sTM, sTF, D-Dimer, PAP, Factor VIII,
TFPI, vWF and fibrinogen in subjects with and without
CKD. Increased levels of smaller molecular weight mole-
cules such as sTM and sTF may be a direct result of
decreased renal clearance. Elevations of larger molecules
may represent increased fibrinolytic activity and higher
clot burden of a thrombotic milieu induced by declining
kidney function. Alternatively, the atherosclerotic process
may differ fundamentally in persons with lower eGFR.
Further investigations may lead to a better understanding
of the mechanisms underlying these associations, as well
as the role of these associations in predicting cardiovascu-
lar disease in subjects with elevated cystatin C.
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